CU6
Clarity Pharmaceuticals Ltd
$1.80
▼ -6.25%
Market cap
$672M
Turnover
$6,915,703
Last price
$1.80
Day change
-6.25%
Announcements
10
Range, past year
Open 4.880 · Low 1.785 · Now 1.800 · High 5.870
Open CU6 in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
CU6 momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-10-13.
Momentum quality
28/100
Wyckoff phase
Downtrend38d
Trend stage
Breakdown
1 Day
-6.2%
1 Week
-10.9%
1 Month
-15.9%
1 Year
-66.5%
RSI
31
Avg daily range
6.8%
Clarity Pharmaceuticals Ltd scores 28 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 38 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -37.1%
- High volatility (ATR 6.8%)
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsCU6 announcements
Recent price-sensitive releases.
- 2026-10-08 SECuRE update Progress Report
- 2026-08-27 Preliminary Final Report Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-08-06 Bioshares Biotech Summit Presentation Company Presentation
- 2026-08-05 SECuRE update Progress Report
- 2026-07-31 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-06-29 Data on SAR-bisPSMA to be presented at EANM
- 2026-05-14 Clarity receives $9.8 million R&D tax incentive refund
More Health Care stocks
Most traded in the same sector.